NCT02608268 - Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies | Biotech Hunter

Enrollment

252

Participants

Timeline

Start Date

November 23, 2015

Primary Completion Date

August 30, 2022

Study Completion Date

August 30, 2022

Conditions

Advanced Malignancies

Interventions

DRUG

MBG453

Anti human TIM-3 monoclonal antibody. MBG453 administered via intravenous (i.v.) infusion either every 2 weeks (Q2W) or every 4 weeks (Q4W).

DRUG

PDR001

Anti-human PD-1 monoclonal antibody. PDR001 administered via intravenous (i.v.) infusion either every 2 weeks (Q2W) or every 4 weeks (Q4W).

DRUG

Decitabine

commercially available chemotherapy

Trial Locations (14)

10002

Novartis Investigative Site, Taipei

20089

Novartis Investigative Site, Rozzano

20141

Novartis Investigative Site, Milan

21231

Sidney Kimmel CCC At JH Sidney Kimmel CCC, Baltimore

77030

UT M.D Anderson Cancer Center, Houston

78229

Mays Cancer Ctr Uthsa Mdacc, San Antonio

168583

Novartis Investigative Site, Singapore

02215

Dana Farber Cancer Institute DFCI - Brookline, Boston

M5G 2C1

Novartis Investigative Site, Toronto

277 8577

Novartis Investigative Site, Kashiwa

1066 CX

Novartis Investigative Site, Amsterdam

2300 RC

Novartis Investigative Site, Leiden

03080

Novartis Investigative Site, Seoul

CH 1211

Novartis Investigative Site, Geneva